DBVT Company Profile and Key Details

Q: Who are the executives of DBVT?

Ms. Lucie MondouletSenior Vice President & Deputy CSOAnne PollakHead of Investor RelationsMs. Michele F. RobertsonChief Legal OfficerMr. Daniel TasséChief Executive Officer & DirectorDr. Pharis MohideenChief Medical OfficerMr. Pascal WotlingChief Technical Operations Officer & Chief Quality OfficerJoseph BeckerVice President of Global Corporation CommunicationsMs. Caroline DaniereChief HR Officer & Chief of StaffDr. Wence AgbotounouChief Clinical Trial Officer & Senior Vice PresidentMr. Sébastien RobitailleChief Financial OfficerMr. Edward P. Jordan M.B.A.Chief Commercial Officer

NASDAQ : DBVT

DBV Technologies SA

$13.50

-0.31-2.25%

At Close 4:00 PM

76.96

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

DBV Technologies S.A. (DBVT) stock declined over -2.24%, trading at $13.50 on NASDAQ, down from the previous close of $13.81. The stock opened at $13.71, fluctuating between $13.00 and $13.73 in the recent session.

Stock Snapshot

13.81

Prev. Close

322.94M

Market Cap

Day Low

-3.03

P/E Ratio

-4.46

EPS (TTM)

-0.42

Cash Flow per Share

13.71

Open

23.92M

Number of Shares

13.73

Day High

99.82%

Free Float in %

0.73

Book Value

351.22K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 31, 2026	13.71	13.73	13.00	13.50	351.68K
Jul 30, 2026	13.45	14.05	13.45	13.81	655.71K
Jul 29, 2026	13.72	13.93	13.30	13.73	419.99K
Jul 28, 2026	13.71	13.71	13.14	13.50	365.97K
Jul 27, 2026	13.75	14.13	13.52	13.90	380.75K
Jul 24, 2026	13.74	13.79	13.39	13.63	190.91K
Jul 23, 2026	13.44	13.95	13.22	13.86	100.69K
Jul 22, 2026	14.24	14.24	13.39	13.63	210.37K
Jul 21, 2026	14.34	14.47	13.88	14.22	478.94K
Jul 20, 2026	14.22	14.61	14.02	14.57	423.19K
Jul 17, 2026	15.05	15.37	14.25	14.70	566.17K
Jul 16, 2026	15.82	16.10	14.77	14.86	378.47K
Jul 15, 2026	15.74	16.03	15.24	15.71	142.94K
Jul 14, 2026	15.98	16.70	15.87	15.92	252.51K
Jul 13, 2026	16.20	16.48	15.63	15.98	129.64K
Jul 10, 2026	16.19	16.61	15.95	16.49	151.1K
Jul 09, 2026	16.71	16.71	16.00	16.08	109.74K
Jul 08, 2026	17.10	17.43	16.27	16.75	137.32K
Jul 07, 2026	16.05	17.39	15.78	17.35	366.1K
Jul 06, 2026	15.80	16.03	15.04	15.61	159.1K

Contact Details

Montrouge, 92120

France

https://www.dbv-technologies.com 331 554 27878

About Company

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

Stock Peers

ARGX

-18.76-2.15%

argenx SE$853.82 REGN

24.29+3.29%

Regeneron Pharmaceuticals, Inc.$762.63 UTHR

-8.11-1.54%

United Therapeutics Corporation$517.71 VRTX

-4.6-0.95%

Vertex Pharmaceuticals Incorporated$477.10 MDGL

-25.79-5.23%

Madrigal Pharmaceuticals, Inc.$467.32 KRYS

-25.73-7.01%

Krystal Biotech, Inc.$341.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-6.07-1.88%

BeOne Medicines AG$316.01 PRAX

0.08+0.03%

Praxis Precision Medicines, Inc.$307.83 LGND

-8.75-2.95%

Ligand Pharmaceuticals Incorporated$287.54

Company Overview

DBV Technologies S.A. (NASDAQ:DBVT) closed at $13.50 USD, losing -$0.31 (-2.24%) from the previous close of $13.81. The stock is currently mid-range between its 52-week high and low $8.66 and $26.18. With a market capitalization of about $322.94 million, DBV Technologies S.A. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.21). Key stats such as the average daily volume over the past year has been around 278.72 thousand shares, in line with its 52-week average. Headquartered in Châtillon, None, DBV Technologies S.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel Tassé, the company employs approximately 161 people and listed since October 22, 2014. DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions.

Technical Performance

DBVT has shown sold momentum, gaining 16.51% over the past week and 23.24% over the past quarter, though year-to-date performance is up 8.97%. Short-term trend indicators are bearishly aligned (SMA20 -1.52%, SMA50 4.14%, SMA200 57.47%). The stock’s 14-day RSI is 50.86 (neutral), while the ATR of 1.48 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.82% below its high and over 463.35% above its low. Average 10-day trading volume of 350.56 thousand shares is slightly above the 3-month average of 281.65 thousand, indicating heightened recent market interest.

Valuation Metrics

DBV Technologies S.A. trades at a P/E ratio of -6.81, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.2 trading at moderately above to book value. The P/FCF stands at -1.61, also below market averages.

Dividend & Fair Value

DBV Technologies S.A. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.00. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

DBV Technologies S.A. generated EPS of -$5.24 over the past year. Five-year average earnings growth is 24.08%. Wall Street analysts project EPS growth of 36.05% annually over the next five years. The latest quarter delivered EPS of -$0.60. The next quarter is forecast at -$0.20. Next year's EPS is expected at -$4.40. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $20.00. The high target offers 307.41% upside. The low target suggests 48.15% downside. The mean target is $44.23. This offers 227.63% upside. DBV Technologies S.A. earnings surprise history is a mixed track record. The quarter that ended July 16, 2026, missed forecasts by 400.0%. The prior quarter beat by 300.0%. Over the last six quarters, Apple has recorded several small beats. These include 638.1% in July 29, 2025.

Shareholding & Insider Activity

DBV Technologies S.A. has 59.18 million shares outstanding. The public float is 35.25 million shares, elevated short interest at 2.49% of float. This equals 1.47 million shares. The short ratio is 5.4 days. Institutional investors hold 37.21% of the float. Insiders own 0.0%. EPIC Bpifrance holds 7.30 million shares, Mohideen Pharis has 145.00 thousand shares and SOLAND DANIEL B has 20.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, DBV Technologies SA generated $15.73M in revenue, or $0.08 per share. Gross margin was 128.59%, operating margin -585.97%, and net profit margin -462.40%. Returns are negative, with ROA at -39.74% and ROE at -51.88%.
On valuation metrics, DBV Technologies SA trades at a P/E of -6.81, P/S of 0.00 and P/B of 7.20. The current ratio is 3.72 and quick ratio is 3.72. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1005.87 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.13, supported by a cash flow-to-debt ratio of -9.51.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, DBV Technologies SA posted revenue of $15.73M, down slightly from $4.80M in the prior quarter. Gross profit was $20.23M (margin 128.59%). Operating income was - $92.16M (margin -586.0%). Net income was- $72.73M (EPS - $0.38).
The company ended the quarter with $141.37M in cash and short-term investments, a total debt of $14.38M, and net debt of - $126.99M. Total assets were $182.99M, with equity of $140.19M. Financials further reflected weakness, with operating cash flow of - $79.65M, free cash flow of - $80.33M, and capital expenditures of - $677.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that DBV Technologies S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.44%, with price expected at $11.82 by August 13, 2026, within a range of $11.19 to $12.51 3-Month Outlook: Projected rise of 27.48%, reaching $17.21 by October 28, 2026, with a range of $16.86 to $17.61. 1-Year Outlook: Projected gain of 49.85%, with price at $20.23 by July 30, 2027, within a range of $19.96 to $20.44.

Key Takeaways

DBV Technologies S.A. (NASDAQ:DBVT) shares are flat 8.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows DBV Technologies S.A. trading at a premium to the broader market with a P/E of -6.81. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $24.14, suggesting 78.81% upside. Our AI forecast model points to short-term weakness (-12.44% over two weeks), a medium-term rise (27.48% over three months), and a longer-term gain (49.85% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current DBV Technologies S.A. (DBVT) stock price?

DBV Technologies S.A. (NASDAQ: DBVT) stock price is $13.50 in the last trading session. During the trading session, DBVT stock reached the peak price of $13.73 while $13.00 was the lowest point it dropped to. The percentage change in DBVT stock occurred in the recent session was -2.24% while the dollar amount for the price change in DBVT stock was - $0.31.

DBVT's industry and sector of operation?

The NASDAQ listed DBVT is part of Biotechnology industry that operates in the broader Healthcare sector. DBV Technologies S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DBVT?

Ms. Lucie Mondoulet
Senior Vice President & Deputy CSO
Anne Pollak
Head of Investor Relations
Ms. Michele F. Robertson
Chief Legal Officer
Mr. Daniel Tassé
Chief Executive Officer & Director
Dr. Pharis Mohideen
Chief Medical Officer
Mr. Pascal Wotling
Chief Technical Operations Officer & Chief Quality Officer
Joseph Becker
Vice President of Global Corporation Communications
Ms. Caroline Daniere
Chief HR Officer & Chief of Staff
Dr. Wence Agbotounou
Chief Clinical Trial Officer & Senior Vice President
Mr. Sébastien Robitaille
Chief Financial Officer
Mr. Edward P. Jordan M.B.A.
Chief Commercial Officer

How DBVT did perform over past 52-week?

DBVT's closing price is 55.8% higher than its 52-week low of $8.67 where as its distance from 52-week high of $26.19 is -48.44%.

How many employees does DBVT have?

Number of DBVT employees currently stands at 161.

Link for DBVT official website?

Official Website of DBVT is: https://www.dbv-technologies.com

How do I contact DBVT?

DBVT could be contacted at phone 331 554 27878 and can also be accessed through its website. DBVT operates from 177-181 Avenue Pierre Brossolette, Montrouge, 92120, France.

How many shares of DBVT are traded daily?

DBVT stock volume for the day was 351.22K shares. The average number of DBVT shares traded daily for last 3 months was 278.72K.

What is the market cap of DBVT currently?

The market value of DBVT currently stands at $322.94M with its latest stock price at $13.50 and 23.92M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	161
Beta	-0.21
Sales or Revenue	$15.73M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

DBVT Company Profile and Key Details

DBV Technologies SA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics